The pill called Amycretin could bring about weight loss of as much as 13% in three months, potentially serving as a new option alongside Ozempic.
In trials, the average person lost 10.4% of their body weight when using Amycretin, significantly more compared to just 1.1% for the placebo group.
Researchers noted that subjects taking Amycretin had not plateaued in their weight loss, suggesting the possibility of further weight loss with continued use.
A single molecule that targets both amylin and GLP-1 biology in a tablet form could offer a more convenient approach to achieving better outcomes.
Collection
[
|
...
]